Skip to content

G&A at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
$62.2M-6.5%
Progyny logo
ProgynyPGNY
$30.81M-9.0%
Pediatrix Medical Group logo
Pediatrix Medical GroupMD
$60.27M+2.8%
NeoGenomics logo
NeoGenomicsNEO
$65.74M-3.6%
GRAIL, Inc. logo
GRAIL, Inc.GRAL
$42.77M-5.1%

Other financials

Income statement

See full
Revenue$14.0K-63.2%
Operating income-$9.4M-1.2%
Net income-$8.4M-2.6%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$4.2M-20.2%
Total debt$2.5M+286%
Total equity$67.6M-28.7%
Total assets$93.5M-20.8%

Cash flow

See full
Operating cash flow-$8.8M-16.2%
CapEx$8.0K+167%
Free cash flow-$8.8M-16.2%

Valuation

See full
Market cap$71.27M+5.0%
Enterprise value$69.6M+9.6%
P/S1,250.3×+622×

Profitability

See full
Operating margin-64,235.1%-8,092,342pp
Net margin-56,386%+1,586,573pp
FCF margin-48,377.2%-673,104pp

Returns & leverage

See full
Return on equity-39.6%-1.6pp
Debt / equity0.0×
Current ratio2.1×+0.1×

Where this comes from

Reported directly by Sera Prognostics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Sera Prognostics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sera Prognostics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sera Prognostics's G&A?
Sera Prognostics (SERA) reported G&A of $4.29M in Q1 2026.
How has Sera Prognostics's G&A changed year-over-year?
Sera Prognostics's G&A decreased by 3.5% year-over-year, from $4.44M to $4.29M.
What is the long-term trend for Sera Prognostics's G&A?
Over 4 years (2021 to 2025), Sera Prognostics's G&A has grown at a 4.3% compound annual growth rate (CAGR), from $14.09M to $16.7M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.